Intraocular implants for extended drug delivery: Therapeutic applications

Advanced Drug Delivery Reviews

Volumn 58, Issue 11, 2006, Pages 1182-1202

  Bourges, J L ^a,b,c,d   Bloquel, C ^a,d   Thomas, A ^a,d   Froussart, F ^a,d   Bochot, A ^c,d   Azan, F ^c,d   Gurny, R ^d,e   BenEzra, D ^a,d,f   Behar Cohen, F ^a,b,c,d  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔTEL DIEU   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e UNIVERSITY OF GENEVA   (Switzerland)

^f HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Drug delivery; Liposomes; Microparticles; Nanoparticles; Ocular implants; Particulate drug delivery systems; Polymers

Indexed keywords

CELLS; DRUG PRODUCTS; IMPLANTS (SURGICAL); INTRAOCULAR LENSES; NANOSTRUCTURED MATERIALS; OPHTHALMOLOGY; POLYMERS; TISSUE;

DRUG DELIVERY; LIPOSOMES; OCULAR IMPLANTS; PARTICULATE DRUG DELIVERY SYSTEMS;

CONTROLLED DRUG DELIVERY;

ANTIRETROVIRUS AGENT; BETAMETHASONE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN A; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ESTER DERIVATIVE; ETHYLENE VINYL ACETATE COPOLYMER; ETOPOSIDE; FLUCONAZOLE; FLUOCINOLONE ACETONIDE; FLUOROURACIL; FLUOROURIDINE; GANCICLOVIR; HEPARIN; HYDROXYPROLINE; INDOMETACIN; MAGNESIUM HYDROXIDE; MITOMYCIN C; PACLITAXEL; POLYANETHOLESULFONIC ACID; POLYANHYDRIDE; POLYCAPROLACTONE; POLYLACTIC ACID; POLYSULFONE; TRIAMCINOLONE ACETONIDE; TSUKUBAENOLIDE; UNINDEXED DRUG;

ANTERIOR EYE CHAMBER; ANTERIOR EYE SEGMENT; CATARACT; CHOROID; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; EYE DISEASE; GRAFT REJECTION; HUMAN; INFLAMMATION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETINA; RETINA DISEASE; RETINITIS; RETINOPATHY; REVIEW; TISSUE ENGINEERING; UNSPECIFIED SIDE EFFECT; UVEITIS;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; EYE DISEASES; HUMANS; PHARMACEUTICAL PREPARATIONS; POLYMERS;

EID: 33751268869     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2006.07.026     Document Type: Review

References (141)

1. Smith T.J., Pearson P.A., Blandford D.L., Brown J.D., Goins K.A., Hollins J.L., Schmeisser E.T., Glavinos P., Baldwin L.B., and Ashton P. Intravitreal sustained-release ganciclovir. Arch. Ophthalmol. 110 (1992) 255-258
2. Driot J.Y., Novack G.D., Rittenhouse K.D., Milazzo C., and Pearson P.A. Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. J. Ocular Pharmacol. Ther. 20 (2004) 269-275
3. Lim J.I., Wolitz R.A., Dowling A.H., Bloom H.R., Irvine A.R., and Schwartz D.M. Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis. Am. J. Ophthalmol. 127 (1999) 288-293
4. Blandford D.L., Smith T.J., Brown J.D., Pearson P.A., and Ashton P. Subconjunctival sustained release 5-fluorouracil. Invest. Ophthalmol. Visual Sci. 33 (1992) 3430-3435
5. Smith T.J., and Ashton P. Sustained-release subconjunctival 5-fluorouracil. Ophthalmic Surg. Lasers 27 (1996) 763-767
6. Okabe K., Kimura H., Okabe J., Kato A., Kunou N., and Ogura Y. Intraocular tissue distribution of betamethasone after intrascleral administration using a non-biodegradable sustained drug delivery device. Invest. Ophthalmol. Visual Sci. 44 (2003) 2702-2707
7. Rahimy M.H., Peyman G.A., Chin S.Y., Golshani R., Aras C., Borhani H., and Thompson H. Polysulfone capillary fiber for intraocular drug delivery: in vitro and in vivo evaluations. J. Drug Target. 2 (1994) 289-298
8. Vert M., Li S.M., and Garreau H. More about the degradation of LA/GA-derived matrices in aqueous media. J. Control. Release 16 (1991) 15
9. Miller R.A., Brady J.M., and Cutright D.E. Degradation rates of oral resorbable implants (polylactates and polyglycolates): rate modification with changes in PLA/PGA copolymer ratios. J. Biomed. Mater. Res. 11 (1977) 711-719
10. Yasukawa T., Kimura H., Tabata Y., and Ogura Y. Biodegradable scleral plugs for vitreoretinal drug delivery. Adv. Drug Deliv. Rev. 52 (2001) 25-36
11. Yasukawa T., Ogura Y., Sakurai E., Tabata Y., and Kimura H. Intraocular sustained drug delivery using implantable polymeric devices. Adv. Drug Deliv. Rev. 57 (2005) 2033-2046
12. Kunou N., Ogura Y., Yasukawa T., Kimura H., Miyamoto H., Honda Y., and Ikada Y. Long-term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirus retinitis. J. Control. Release 68 (2000) 263-271
13. Peyman G.A., Khoobehi B., Shaibani S., Shamsnia S., and Ribeiro I. A fluorescent vesicle system for the measurement of blood velocity in the choroidal vessels. Ophthalmic Surg. Lasers 27 (1996) 459-466
14. Dong X., Shi W., Yuan G., Xie L., Wang S., and Lin P. Intravitreal implantation of the biodegradable cyclosporin A drug delivery system for experimental chronic uveitis. Graefe Arch. Clin. Exp. Ophthalmol. 244 (2006) 492-497
15. Shi W., Liu T., Xie L., and Wang S. FK506 in a biodegradable glycolide-co-clatide-co-caprolactone polymer for prolongation of corneal allograft survival. Curr. Eye Res. 30 (2005) 969-976
16. Leong K., Simonte V., and Langer R. Synthesis of polyanhydrides-melt-polycondensation, dehydrochlorination, and dehydrative coupling. Macromolecules 20 (1987) 705-712
17. Leong K.W., Brott B.C., and Langer R. Bioerodible polyanhydrides as drug-carrier matrices. I: characterization, degradation, and release characteristics. J. Biomed. Mater. Res. 19 (1985) 941-955
18. Leong K.W., D'Amore P.D., Marletta M., and Langer R. Bioerodible polyanhydrides as drug-carrier matrices. II. Biocompatibility and chemical reactivity. J. Biomed. Mater. Res. 20 (1986) 51-64
19. Heller J., Barr J., Ng S.Y., Shen H.R., Schwach-Abdellaoui K., Einmahl S., Rothen-Weinhold A., and Gurny R. Poly(ortho esters) - their development and some recent applications. Eur. J. Pharm. Biopharm. 50 (2000) 121-128
20. Heller J. Ocular delivery using poly(ortho esters). Adv. Drug Deliv. Rev. 57 (2005) 2053-2062
21. Einmahl S., Capancioni S., Schwach-Abdellaoui K., Moeller M., Behar-Cohen F., and Gurny R. Therapeutic applications of viscous and injectable poly(ortho esters). Adv. Drug Deliv. Rev. 53 (2001) 45-73
22. Merkli A., Heller J., Tabatabay C., and Gurny R. Synthesis and characterization of a new biodegradable semi-solid poly(ortho ester) for drug delivery systems. J. Biomater. Sci., Polym. Ed. 4 (1993) 505-516
23. Zignani M., Merkli A., Sintzel M.B., Bernatchez S.F., Kloeti W., Heller J., Tabatabay C., and Gurny R. New generation of poly(ortho esters): synthesis, characterization, kinetics, sterilization and biocompatibility. J. Control. Release 48 (1997) 115-129
24. Einmahl S., Zignani M., Varesio E., Heller J., Veuthey J., Tabatabay C., and Gurny R. Concomitant and controlled release of dexamethasone and 5-fluorouracil from poly(ortho ester). Int. J. Pharm. 20 (1999) 189-198
25. Zignani M., Einmahl S., Baeyens V., Varesio E., Veuthey J.L., Anderson J., Heller J., Tabatabay C., and Gurny R. A poly(ortho ester) designed for combined ocular delivery of dexamethasone sodium phosphate and 5-fluorouracil: subconjunctival tolerance and in vitro release. Eur. J. Pharm. Biopharm. 50 (2000) 251-255
26. Zignani M., Le Minh T., Einmahl S., Tabatabay C., Heller J., Anderson J.M., and Gurny R. Improved biocompatibility of a viscous bioerodible poly(ortho ester) by controlling the environmental pH during degradation. Biomaterials 21 (2000) 1773-1778
27. Merkli A., Heller J., Tabatabay C., and Gurny R. Semi-solid hydrophobic bioerodible poly (ortho ester) for potential application in glaucoma filtering surgery. J. Control. Release 29 (1994) 105-112
28. Sintzel M.B., Schwach-Abdellaoui K., Mäder K., Stösser R., Heller J., Tabatabay C., and Gurny R. Influence of irradiation serilization on a semi-solid poly(ortho ester). Int. J. Pharm. 175 (1998) 165-176
29. Merkli A., Heller J., Tabatabay C., and Gurny R. Purity and stability assessment of a semi-solid poly(ortho ester) used in drug delivery systems. Biomaterials 17 (1996) 897-902
30. Bernatchez S.F., Merkli A., Minh T.L., Tabatabay C., Anderson J.M., and Gurny R. Biocompatibility of a new semisolid bioerodible poly(ortho ester) intended for the ocular delivery of 5-fluorouracil. J. Biomed. Mater. Res. 28 (1994) 1037-1046
31. Zignani M., Bernatchez S.F., Le Minh T., Tabatabay C., Anderson J.M., and Gurny R. Subconjunctival biocompatibility of a viscous bioerodable poly(ortho ester). J. Biomed. Mater. Res. 39 (1998) 277-285
32. Einmahl S., Behar-Cohen F., Tabatabay C., Savoldelli M., D'Hermies F., Chauvaud D., Heller J., and Gurny R. A viscous bioerodible poly(ortho ester) as a new biomaterial for intraocular application. J. Biomed. Mater. Res. 50 (2000) 566-573
33. Einmahl S., Savoldelli M., D'Hermies F., Tabatabay C., Gurny R., and Behar-Cohen F. Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye. Invest. Ophthalmol. Visual Sci. 43 (2002) 1533-1539
34. Ng S.Y., Shen H.R., Lopez E., Zherebin Y., Barr J., Schacht E., and Heller J. Development of a poly(ortho ester) prototype with a latent acid in the polymer backbone for 5-fluorouracil delivery. J. Control. Release 65 (2000) 367-374
35. Sintzel M.B., Heller J., Ng S.Y., Taylor M.S., Tabatabay C., and Gurny R. Synthesis and characterization of self-catalyzed poly(ortho ester). Biomaterials 19 (1998) 791-800
36. Schwach-Abdellaoui K., Heller J., and Gurny R. Synthesis and characterization of self-catalyzed poly(ortho-esters) based on decanediol and decanediol-lactate. J. Biomater. Sci., Polym. Ed. 10 (1999) 375-389
37. Einmahl S., Ponsart S., Bejjani R.A., D'Hermies F., Savoldelli M., Heller J., Tabatabay C., Gurny R., and Behar-Cohen F. Ocular biocompatibility of a poly(ortho ester) characterized by autocatalyzed degradation. J. Biomed. Mater. Res. A 67 (2003) 44-53
38. Wyszynski R.E., Vahey J.B., Manning L., Bruner W.E., Morgan K.M., and Burney E.N. Sustained release of 5-fluorouracil from ethylene acetate copolymer. J. Ocul. Pharmacol. 5 (1989) 141-146
39. Trope G.E., Cheng Y.L., Sheardown H., Liu G.S., Menon I.A., Heathcote J.G., Rootman D.S., Chiu W.J., and Gould L. Depot drug delivery system for 5-fluorouracil after filtration surgery in the rabbit. Can. J. Ophthalmol. 29 (1994) 263-267
40. Gould L., Trope G., Cheng Y.L., Heathcote J.G., Sheardown H., Rootman D., Liu G.S., and Menon I.A. Fifty:fifty poly (dl glycolic acid-lactic acid) copolymer as a drug delivery system for 5-fluorouracil: a histopathological evaluation. Can. J. Ophthalmol. 29 (1994) 168-171
41. Hostyn P., Villain F., Malek-Chehire N., Kuhne F., Takesue Y., Parrish II R.K., and Parel J.M. Biodegradable controlled-release 5-FU implant in the surgery for glaucoma. Experimental study. J. Fr. Ophtalmol. 19 (1996) 133-139
42. Wang G., Tucker I.G., Roberts M.S., and Hirst L.W. In vitro and in vivo evaluation in rabbits of a controlled release 5-fluorouracil subconjunctival implant based on poly(d,l-lactide-co-glycolide). Pharm. Res. 13 (1996) 1059-1064
43. Wang Y., Challa P., Epstein D.L., and Yuan F. Controlled release of ethacrynic acid from poly(lactide-co-glycolide) films for glaucoma treatment. Biomaterials 25 (2004) 4279-4285
44. Seah S.K., Husain R., Gazzard G., Lim M.C., Hoh S.T., Oen F.T., and Aung T. Use of Surodex in phacotrabeculectomy surgery. Am. J. Ophthalmol. 139 (2005) 927-928
45. Lee D.A., Flores R.A., Anderson P.J., Leong K.W., Teekhasaenee C., de Kater A.W., and Hertzmark E. Glaucoma filtration surgery in rabbits using bioerodible polymers and 5-fluorouracil. Ophthalmology 94 (1987) 1523-1530
46. Lee D.A., Leong K.W., Panek W.C., Eng C.T., and Glasgow B.J. The use of bioerodible polymers and 5-fluorouracil in glaucoma filtration surgery. Invest. Ophthalmol. Visual Sci. 29 (1988) 1692-1697
47. Jampel H.D., Leong K.W., Dunkelburger G.R., and Quigley H.A. Glaucoma filtration surgery in monkeys using 5-fluorouridine in polyanhydride disks. Arch. Ophthalmol. 108 (1990) 430-435
48. Charles J.B., Ganthier Jr. R., Wilson M.R., Lee D.A., Baker R.S., Leong K.W., and Glasgow B.J. Use of bioerodible polymers impregnated with mitomycin in glaucoma filtration surgery in rabbits. Ophthalmology 98 (1991) 503-508
49. Jampel H.D., Koya P., Leong K., and Quigley H.A. In vitro release of hydrophobic drugs from polyanhydride disks. Ophthalmic Surg. 22 (1991) 676-680
50. Uppal P., Jampel H.D., Quigley H.A., and Leong K.W. Pharmacokinetics of etoposide delivery by a bioerodible drug carrier implanted at glaucoma surgery. J. Ocul. Pharmacol. 10 (1994) 471-479
51. Jampel H.D., Thibault D., Leong K.W., Uppal P., and Quigley H.A. Glaucoma filtration surgery in nonhuman primates using taxol and etoposide in polyanhydride carriers. Invest. Ophthalmol. Visual Sci. 34 (1993) 3076-3083
52. Rabowsky J.H., Dukes A.J., Lee D.A., and Leong K.W. The use of bioerodible polymers and daunorubicin in glaucoma filtration surgery. Ophthalmology 103 (1996) 800-807
53. Einmahl S., Behar-Cohen F., D'Hermies F., Rudaz S., Tabatabay C., Renard G., and Gurny R. A new poly(ortho ester)-based drug delivery system as an adjunct treatment in filtering surgery. Invest. Ophthalmol. Visual Sci. 42 (2001) 695-700
54. BenEzra D. Neovasculogenic ability of prostaglandins, growth factors, and synthetic chemoattractants. Am. J. Ophthalmol. 86 (1978) 455-461
55. BenEzra D., Hemo I., and Maftzir G. In vivo angiogenic activity of interleukins. Arch. Ophthalmol. 108 (1990) 573-576
56. Friling R., Yassur Y., Levy R., Kost J., Schwartz B., Mikhailowsky R., and Lamprecht S.A. A role of transforming growth factor-beta 1 in the control of corneal neovascularization. In Vivo 10 (1996) 59-64
57. Xie L., Shi W., Wang Z., Bei J., and Wang S. Prolongation of corneal allograft survival using cyclosporine in a polylactide-co-glycolide polymer. Cornea 20 (2001) 748-752
58. Theng J.T., Ti S.E., Zhou L., Lam K.W., Chee S.P., and Tan D. Pharmacokinetic and toxicity study of an intraocular cyclosporine DDS in the anterior segment of rabbit eyes. Invest. Ophthalmol. Visual Sci. 44 (2003) 4895-4899
59. Kagaya F., Usui T., Kamiya K., Ishii Y., Tanaka S., Amano S., and Oshika T. Intraocular dexamethasone delivery system for corneal transplantation in an animal model. Cornea 21 (2002) 200-202
60. Chang D.F., Garcia I.H., Hunkeler J.D., and Minas T. Phase II results of an intraocular steroid delivery system for cataract surgery. Ophthalmology 106 (1999) 1172-1177
61. Tan D.T., Chee S.P., Lim L., Theng J., and Van Ede M. Randomized clinical trial of Surodex steroid drug delivery system for cataract surgery: anterior versus posterior placement of two Surodex in the eye. Ophthalmology 108 (2001) 2172-2181
62. Wadood A.C., Armbrecht A.M., Aspinall P.A., and Dhillon B. Safety and efficacy of a dexamethasone anterior segment drug delivery system in patients after phacoemulsification. J. Cataract Refract. Surg. 30 (2004) 761-768
63. Kodama M., Numaga J., Yoshida A., Kaburaki T., Oshika T., Fujino Y., Wu G.S., Rao N.A., and Kawashima H. Effects of a new dexamethasone-delivery system (Surodex) on experimental intraocular inflammation models. Graefe Arch. Clin. Exp. Ophthalmol. 241 (2003) 927-933
64. Nishi O., Nishi K., Morita T., Tada Y., Shirasawa E., and Sakanishi K. Effect of intraocular sustained release of indomethacin on postoperative inflammation and posterior capsule opacification. J. Cataract Refract. Surg. 22 Suppl 1 (1996) 806-810
65. Nishi O., Nishi K., Saitoh I., and Sakanishi K. Inhibition of migrating lens epithelial cells by sustained release of ethylenediaminetetraacetic acid. J. Cataract Refract. Surg. 22 Suppl 1 (1996) 863-868
66. Pandey S.K., Cochener B., Apple D.J., Colin J., Werner L., Bougaran R., Trivedi R.H., Macky T.A., and Izak A.M. Intracapsular ring sustained 5-fluorouracil delivery system for the prevention of posterior capsule opacification in rabbits: a histological study. J. Cataract Refract. Surg. 28 (2002) 139-148
67. Xie L., Sun J., and Yao Z. Heparin drug delivery system for prevention of posterior capsular opacification in rabbit eyes. Graefe Arch. Clin. Exp. Ophthalmol. 241 (2003) 309-313
68. Rahimy M.H., Peyman G.A., Fernandes M.L., el-Sayed S.H., Luo Q., and Borhani H. Effects of an intravitreal daunomycin implant on experimental proliferative vitreoretinopathy: simultaneous pharmacokinetic and pharmacodynamic evaluations. J. Ocul. Pharmacol. 10 (1994) 561-570
69. Hainsworth D.P., Pearson P.A., Conklin J.D., and Ashton P. Sustained release intravitreal dexamethasone. J. Ocular Pharmacol. Ther. 12 (1996) 57-63
70. Yang C.S., Khawly J.A., Hainsworth D.P., Chen S.N., Ashton P., Guo H., and Jaffe G.J. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch. Ophthalmol. 116 (1998) 69-77
71. Rubsamen P.E., Davis P.A., Hernandez E., O'Grady G.E., and Cousins S.W. Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil. Arch. Ophthalmol. 112 (1994) 407-413
72. Hashizoe M., Ogura Y., Takanashi T., Kunou N., Honda Y., and Ikada Y. Implantable biodegradable polymeric device in the treatment of experimental proliferative vitreoretinopathy. Curr. Eye Res. 14 (1995) 473-477
73. Zhou T., Lewis H., Foster R.E., and Schwendeman S.P. Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy. J. Control. Release 55 (1998) 281-295
74. Yasukawa T., Kimura H., Tabata Y., Miyamoto H., Honda Y., and Ogura Y. Sustained release of cis-hydroxyproline in the treatment of experimental proliferative vitreoretinopathy in rabbits. Graefe Arch. Clin. Exp. Ophthalmol. 240 (2002) 672-678
75. Borhani H., Peyman G.A., Rahimy M.H., and Thompson H. Suppression of experimental proliferative vitreoretinopathy by sustained intraocular delivery of 5-FU. Int. Ophthalmol. 19 (1995) 43-49
76. Frenzel E.M., Neely K.A., Walsh A.W., Cameron J.D., and Gregerson D.S. A new model of proliferative vitreoretinopathy. Invest. Ophthalmol. Visual Sci. 39 (1998) 2157-2164
77. Fastenberg D.M., Diddie K.R., Sorgente N., and Ryan S.J. A comparison of different cellular inocula in an experimental model of massive periretinal proliferation. Am. J. Ophthalmol. 93 (1982) 559-564
78. Ashton P., Brown J.D., Pearson P.A., Blandford D.L., Smith T.J., Anand R., Nightingale S.D., and Sanborn G.E. Intravitreal ganciclovir pharmacokinetics in rabbits and man. J. Ocul. Pharmacol. 8 (1992) 343-347
79. Sanborn G.E., Anand R., Torti R.E., Nightingale S.D., Cal S.X., Yates B., Ashton P., and Smith T. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device. Arch. Ophthalmol. 110 (1992) 188-195
80. Anand R., Nightingale S.D., Fish R.H., Smith T.J., and Ashton P. Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir. Arch. Ophthalmol. 111 (1993) 223-227
81. Martin D.F., Parks D.J., Mellow S.D., Ferris F.L., Walton R.C., Remaley N.A., Chew E.Y., Ashton P., Davis M.D., and Nussenblatt R.B. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch. Ophthalmol. 112 (1994) 1531-1539
82. Morley M.G., Duker J.S., Ashton P., and Robinson M.R. Replacing ganciclovir implants. Ophthalmology 102 (1995) 388-392
83. Engstrom Jr. R.E., and Holland G.N. Local therapy for cytomegalovirus retinopathy. Am. J. Ophthalmol. 120 (1995) 376-385
84. Charles N.C., and Steiner G.C. Ganciclovir intraocular implant. A clinicopathologic study. Ophthalmology 103 (1996) 416-421
85. Marx J.L., Kapusta M.A., Patel S.S., LaBree L.D., Walonker F., Rao N.A., and Chong L.P. Use of the ganciclovir implant in the treatment of recurrent cytomegalovirus retinitis. Arch. Ophthalmol. 114 (1996) 815-820
86. Hashizoe M., Ogura Y., Kimura H., Moritera T., Honda Y., Kyo M., Hyon S.H., and Ikada Y. Scleral plug of biodegradable polymers for controlled drug release in the vitreous. Arch. Ophthalmol. 112 (1994) 1380-1384
87. Hashizoe M., Ogura Y., Takanashi T., Kunou N., Honda Y., and Ikada Y. Biodegradable polymeric device for sustained intravitreal release of ganciclovir in rabbits. Curr. Eye Res. 16 (1997) 633-639
88. Musch D.C., Martin D.F., Gordon J.F., Davis M.D., and Kuppermann B.D. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. N. Engl. J. Med. 337 (1997) 83-90
89. Martin D.F., Dunn J.P., Davis J.L., Duker J.S., Engstrom Jr. R.E., Friedberg D.N., Jaffe G.J., Kuppermann B.D., Polis M.A., Whitley R.J., Wolitz R.A., and Benson C.A. Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: recommendations of the International AIDS Society-USA panel. Am. J. Ophthalmol. 127 (1999) 329-339
90. Kunou N., Ogura Y., Hashizoe M., Honda Y., Hyon S., and Ikada Y. Controlled intraocular delivery of ganciclovir with use of biodegradable scleral implant in rabbits. J. Control. Release 37 (1995) 143-150
91. Yasukawa T., Kimura H., Kunou N., Miyamoto H., Honda Y., Ogura Y., and Ikada Y. Biodegradable scleral implant for intravitreal controlled release of ganciclovir. Graefe Arch. Clin. Exp. Ophthalmol. 238 (2000) 186-190
92. Sakurai E., Matsuda Y., Ozeki H., Kunou N., Nakajima K., and Ogura Y. Scleral plug of biodegradable polymers containing ganciclovir for experimental cytomegalovirus retinitis. Invest. Ophthalmol. Visual Sci. 42 (2001) 2043-2048
93. Yamakawa I., Ishida M., Kato T., Ando H., and Asakawa N. Release behavior of poly(lactic acid-co-glycolic acid) implants containing phosphorothioate oligodeoxynucleotide. Biol. Pharm. Bull. 20 (1997) 455-459
94. Hainsworth D.P., Conklin J.D., Bierly J.R., Ax D., and Ashton P. Intravitreal delivery of ciprofloxacin. J. Ocular Pharmacol. Ther. 12 (1996) 183-191
95. Miyamoto H., Ogura Y., Hashizoe M., Kunou N., Honda Y., and Ikada Y. Biodegradable scleral implant for intravitreal controlled release of fluconazole. Curr. Eye Res. 16 (1997) 930-935
96. Morita Y., Ohtori A., Kimura M., and Tojo K. Intravitreous delivery of dexamethasone sodium m-sulfobenzoate from poly(dl-lactic acid) implants. Biol. Pharm. Bull. 21 (1998) 188-190
97. Cheng C.K., Berger A.S., Pearson P.A., Ashton P., and Jaffe G.J. Intravitreal sustained-release dexamethasone device in the treatment of experimental uveitis. Invest. Ophthalmol. Visual Sci. 36 (1995) 442-453
98. Pearson P.A., Jaffe G.J., Martin D.F., Cordahi G.J., Grossniklaus H., Schmeisser E.T., and Ashton P. Evaluation of a delivery system providing long-term release of cyclosporine. Arch. Ophthalmol. 114 (1996) 311-317
99. Jaffe G.J., Yang C.S., Wang X.C., Cousins S.W., Gallemore R.P., and Ashton P. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology 105 (1998) 46-56
100. Enyedi L.B., Pearson P.A., Ashton P., and Jaffe G.J. An intravitreal device providing sustained release of cyclosporine and dexamethasone. Curr. Eye Res. 15 (1996) 549-557
101. Jaffe G.J., Yang C.H., Guo H., Denny J.P., Lima C., and Ashton P. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest. Ophthalmol. Visual Sci. 41 (2000) 3569-3575
102. Jaffe G.J., Ben-Nun J., Guo H., Dunn J.P., and Ashton P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology 107 (2000) 2024-3320
103. Jaffe G.J., McCallum R.M., Branchaud B., Skalak C., Butuner Z., and Ashton P. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 112 (2005) 1192-1198
104. Jaffe G.J., Martin D., Callanan D., Pearson P.A., Levy B., and Comstock T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 113 (2006) 1020-1027
105. Beeley N.R., Stewart J.M., Tano R., Lawin L.R., Chappa R.A., Qiu G., Anderson A.B., de Juan E., and Varner S.E. Development, implantation, in vivo elution, and retrieval of a biocompatible, sustained release subretinal drug delivery system. J. Biomed. Mater. Res. A 76 (2006) 690-698
106. Kato A., Kimura H., Okabe K., Okabe J., Kunou N., and Ogura Y. Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant. Invest. Ophthalmol. Visual Sci. 45 (2004) 238-244
107. Kim H., Robinson M.R., Lizak M.J., Tansey G., Lutz R.J., Yuan P., Wang N.S., and Csaky K.G. Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Invest. Ophthalmol. Visual Sci. 45 (2004) 2722-2731
108. Sakurai E., Nozaki M., Okabe K., Kunou N., Kimura H., and Ogura Y. Scleral plug of biodegradable polymers containing tacrolimus (FK506) for experimental uveitis. Invest. Ophthalmol. Visual Sci. 44 (2003) 4845-4852
109. Ciulla T.A., Criswell M.H., Danis R.P., Fronheiser M., Yuan P., Cox T.A., Csaky K.G., and Robinson M.R. Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants. Br. J. Ophthalmol. 87 (2003) 1032-1037
110. Uteza Y., Rouillot J.S., Kobetz A., Marchant D., Pecqueur S., Arnaud E., Prats H., Honiger J., Dufier J.L., Abitbol M., and Neuner-Jehle M. Intravitreous transplantation of encapsulated fibroblasts secreting the human fibroblast growth factor 2 delays photoreceptor cell degeneration in Royal College of Surgeons rats. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 3126-3131
111. Tao W., Wen R., Goddard M.B., Sherman S.D., O'Rourke P.J., Stabila P.F., Bell W.J., Dean B.J., Kauper K.A., Budz V.A., Tsiaras W.G., Acland G.M., Pearce-Kelling S., Laties A.M., and Aguirre G.D. Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest. Ophthalmol. Visual Sci. 43 (2002) 3292-3298
112. Bush R.A., Lei B., Tao W., Raz D., Chan C.C., Cox T.A., Santos-Muffley M., and Sieving PA. Encapsulated cell-based intraocular delivery of ciliary neurotrophic factor in normal rabbit: dose-dependent effects on ERG and retinal histology. Invest. Ophthalmol. Visual Sci. 45 (2004) 2420-2430
113. Thanos C.G., Bell W.J., O'Rourke P., Kauper K., Sherman S., Stabila P., and Tao W. Sustained secretion of ciliary neurotrophic factor to the vitreous, using the encapsulated cell therapy-based NT-501 intraocular device. Tissue Eng. 10 (2004) 1617-1622
114. Sieving P.A., Caruso R.C., Tao W., Coleman H.R., Thompson D.J., Fullmer K.R., and Bush R.A. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 3896-3901
115. Tomita M., Lavik E., Klassen H., Zahir T., Langer R., and Young M.J. Biodegradable polymer composite grafts promote the survival and differentiation of retinal progenitor cells. Stem Cells 23 (2005) 1579-1588
116. Normand N., van Leeuwen H., and O'Hare P. Particle formation by a conserved domain of the herpes simplex virus protein VP22 facilitating protein and nucleic acid delivery. J. Biol. Chem. 276 (2001) 15042-15050
117. Gomes dos Santos A.L., Bochot A., Tsapis N., Artzner F., Bejjani R.A., Thillaye-Goldenberg B., de Kozak Y., Fattal E., and Behar-Cohen F. Oligonucleotide-polyethylenimine complexes targeting retinal cells: structural analysis and application to anti-TGFbeta-2 therapy. Pharm. Res. 23 (2006) 770-781
118. Mainardes R.M., and Silva L.P. Drug delivery systems: past, present, and future. Curr. Drug Targets 5 (2004) 449-455
119. Mainardes R.M., Urban M.C., Cinto P.O., Khalil N.M., Chaud M.V., Evangelista R.C., and Gremiao M.P. Colloidal carriers for ophthalmic drug delivery. Curr. Drug Targets 6 (2005) 363-371
120. Tabata Y., and Ikada Y. Macrophage phagocytosis of biodegradable microspheres composed of l-lactic acid/glycolic acid homo- and copolymers. J. Biomed. Mater. Res. 22 (1988) 837-858
121. de Kozak Y., Andrieux K., Villarroya H., Klein C., Thillaye-Goldenberg B., Naud M.C., Garcia E., and Couvreur P. Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. Eur. J. Immunol. 34 (2004) 3702-3712
122. Ogura Y., and Kimura H. Biodegradable polymer microspheres for targeted drug delivery to the retinal pigment epithelium. Surv. Ophthalmol. 39 Suppl 1 (1995) S17-S24
123. Veloso Jr. A.A., Zhu Q., Herrero-Vanrell R., and Refojo M.F. Ganciclovir-loaded polymer microspheres in rabbit eyes inoculated with human cytomegalovirus. Invest. Ophthalmol. Visual Sci. 38 (1997) 665-675
124. Moritera T., Ogura Y., Yoshimura N., Honda Y., Wada R., Hyon S.H., and Ikada Y. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy. Invest. Ophthalmol. Visual Sci. 33 (1992) 3125-3130
125. Sakurai E., Ozeki H., Kunou N., and Ogura Y. Effect of particle size of polymeric nanospheres on intravitreal kinetics. Ophthalmic Res. 33 (2001) 31-36
126. Bourges J.L., Gautier S.E., Delie F., Bejjani R.A., Jeanny J.C., Gurny R., BenEzra D., and Behar-Cohen F.F. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest. Ophthalmol. Visual Sci. 44 (2003) 3562-3569
127. Bejjani R.A., BenEzra D., Cohen H., Rieger J., Andrieu C., Jeanny J.C., Gollomb G., and Behar-Cohen F.F. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol. Vis. 11 (2005) 124-132
128. Ebrahim S., Peyman G.A., and Lee P.J. Applications of liposomes in ophthalmology. Surv. Ophthalmol. 50 (2005) 167-182
129. Merodio M., Irache J.M., Valamanesh F., and Mirshahi M. Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats. Biomaterials 23 (2002) 1587-1594
130. Khoobehi B., Stradtmann M.O., Peyman G.A., and Aly O.M. Clearance of sodium fluorescein incorporated into microspheres from the vitreous after intravitreal injection. Ophthalmic Surg. 22 (1991) 175-180
131. Moritera T., Ogura Y., Honda Y., Wada R., Hyon S.H., and Ikada Y. Microspheres of biodegradable polymers as a drug-delivery system in the vitreous. Invest. Ophthalmol. Visual Sci. 32 (1991) 1785-1790
132. Giordano G.G., Refojo M.F., and Arroyo M.H. Sustained delivery of retinoic acid from microspheres of biodegradable polymer in PVR. Invest. Ophthalmol. Visual Sci. 34 (1993) 2743-2751
133. Irache J.M., Merodio M., Arnedo A., Camapanero M.A., Mirshahi M., and Espuelas S. Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs. Mini. Rev. Med. Chem. 5 (2005) 293-305
134. Normand N., Valamanesh F., Savoldelli M., Mascarelli F., BenEzra D., Courtois Y., and Behar-Cohen F. VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo. Mol. Vis. 11 (2005) 184-191
135. Bochot A., Couvreur P., and Fattal E. Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery. Prog. Retin. Eye Res. 19 (2000) 131-147
136. Barza M., Stuart M., and Szoka Jr. F. Effect of size and lipid composition on the pharmacokinetics of intravitreal liposomes. Invest. Ophthalmol. Visual Sci. 28 (1987) 893-900
137. Bochot A., Fattal E., Boutet V., Deverre J.R., Jeanny J.C., Chacun H., and Couvreur P. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Invest. Ophthalmol. Visual Sci. 43 (2002) 253-259
138. Peyman G.A., Conway M., Khoobehi B., and Soike K. Clearance of microsphere-entrapped 5-fluorouracil and cytosine arabinoside from the vitreous of primates. Int. Ophthalmol. 16 (1992) 109-113
139. Akula S.K., Ma P.E., Peyman G.A., Rahimy M.H., Hyslop Jr. N.E., Janney A., and Ashton P. Treatment of cytomegalovirus retinitis with intravitreal injection of liposome encapsulated ganciclovir in a patient with AIDS. Br. J. Ophthalmol. 78 (1994) 677-680
140. Andrieu-Soler C., Aubert-Pouessel A., Doat M., Picaud S., Halhal M., Simonutti M., Venier-Julienne M.C., Benoit J.P., and Behar-Cohen F. Intravitreous injection of PLGA microspheres encapsulating GDNF promotes the survival of photoreceptors in the rd1/rd1 mouse. Mol. Vis. 11 (2005) 1002-1011
141. Cleland J.L., Duenas E.T., Park A., Daugherty A., Kahn J., Kowalski J., and Cuthbertson A. Development of poly-(d,l-lactide-coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis. J. Control. Release 72 (2001) 13-24